News
MiNK INKT Q2 2025 Earnings Call Transcript
Phase 2 Clinical Data -- Published results include a complete clinical response in a 49-year-old man with metastatic testicular cancer following a single dose of AGENT-797, with sustained remission beyond two years and no cytokine release syndrome or graft-versus-host disease.
Co-Diagnostics( CODX 0.99%) reported a steep revenue decline in Q2 2025, driven by the absence of grant income. Management ...
Advanced Drainage’s Q2 results received a strong positive market reaction, reflecting resilience in a challenging demand ...
StockStory.org on MSN2h
5 Insightful Analyst Questions From Alta’s Q2 Earnings Call
Alta Equipment Group’s second quarter performance was well received by the market, with management crediting operational ...
Live Updates Live Coverage Has Ended Guidance is In 5:27 pm Here’s what the company said: “Now turning to guidance for Q3 and ...
MCLEAN, VA / ACCESS Newswire / August 11, 2025 / Gladstone Investment Corporation (Nasdaq:GAIN) announces the following event ...
Ronald W. McClurg, CFO, said, "product revenue increased 105% to $1.7 million" and cited "sizable improvements year-over-year ...
Kolibri Global Energy Inc (KGEI) reports increased production and financial flexibility, despite facing revenue declines due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback